Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain. (July 2015)

• Record Type: Journal Article
• Authors: Sandoval, Nancy; Grau, Santiago; Sorlí, Luisa; Montero, Milagro; Esteve, Erika; Horcajada, Juan Pablo
• Is Part Of: Future microbiology. Volume 10:Number 7(2015:Jul.)
• Page Start: 1145
• Page End: 1154
• Publication Date: 2015-07
• Subjects: bacteremia -- clinical outcome -- daptomycin -- Gram-positive infections -- retrospective study; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb.15.41
• Languages: English
• ISSNs: 1746-0913

Abstract

ABSTRACT : Aim: We reviewed the clinical use of daptomycin in daily practice.Materials & methods: Efficacy and safety were assessed in 175 consecutive patients given daptomycin for at least 72 h.Results: Daptomycin was given as rescue treatment in 50.9% of cases. Bloodstream infection (34.8%) and skin/soft-tissue infection (19.4%) were the most frequent. In 62.3% of patients, the dose of ≤ 6 mg/kg/day was administered. Staphylococcus spp. were isolated in 52.6% of cases (MRSA in 9.5%, CoNS in 34.3%) and Enterococcus spp. in 8.7%. Clinical success was 75% and microbiological eradication 48.6%. Two patients discontinued daptomycin due to hemolytic anemia of unlikely and possible relationship with daptomycin, respectively.Conclusion: Daptomycin was effective and well tolerated in patients with severe Gram-positive infections.